Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of telisotuzumab vedotin regimens in c-Met overexpressing EGFR wild-type non-squamous NSCLC
jRCT2021250010Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of telisotuzumab vedotin in non-small cell lung cancer (NSCLC) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of participants with treatment-emergent adverse events (any-grade and Grade >= 2), Percentage of participants with treatment-emergent interstitial lung disease (ILD) and 5 more. Started Oct 2025; status: recruiting.
02
Drugs
telisotuzumab vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2021250010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021250010.